AlphAIAlphAI — Financial news for AI agents
investing.com$JNJ

Why is Johnson & Johnson stock sliding today?

Johnson & Johnson (JNJ) stock fell 2.5% in pre-market trading despite a solid Q3 2026 earnings report. Adjusted EPS beat estimates at $2.59, with revenue of $25.4B, up 5.9% YoY. GAAP EPS dropped 95.9% to $210M due to one-time charges. The company raised its full-year guidance to $11.05–$11.15 adjusted EPS. Medical device sales grew slowly, while pharmaceutical sales rose 7.7%. The stock traded below moving averages, and analysts revised EPS estimates downward.

Original reporting
investing.com
Published Oct 13, 2026, 11:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$JNJ
Bearish
high confidence
Mentioned
$JNJ
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$JNJBearishHigh
01

Why it matters

Earnings beat on adjusted metrics is muted by a GAAP loss and a $5.5 B talc settlement, leading to a modest pre‑market decline.

02

Market read

The earnings release provides fresh data that moves JNJ stock and may influence peer healthcare stocks.

03

What to watch

Potential spin‑off of the orthopedics business and long‑term demand for oncology drugs may provide upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Johnson & Johnson's Q3 earnings were released amid a broader chip sell‑off and AI‑related market concerns.

Company-level read

Ticker impact

$JNJBearishHigh confidence
Context

Johnson & Johnson reported Q3 2026 earnings with adjusted EPS beat, GAAP EPS miss due to a special charge, raised full-year guidance, and the stock slid 2.5% in pre‑open trading.

Expected impact

downward pressure as investors price in the GAAP miss and settlement uncertainty

Evidence & confidence

Pre‑market slide of 2.5% reflects market reaction to the GAAP earnings miss and legal charge despite guidance raise.

Market effects

Sector

Healthcare sector may see broader weakness as investors scrutinize medical device earnings and legal exposures.

Regional

U.S. large‑cap healthcare stocks could face modest sell pressure in early trading.

Global

Limited to U.S. markets; no immediate global macro impact.

Counterpoint

What could challenge this read

The raised full‑year guidance and strong pharma growth could support a rebound if the market overreacts to the GAAP miss.

Key entities

  • company
    Johnson & Johnson

    U.S. healthcare conglomerate reporting Q3 2026 results.

  • company
    Firefly Bio, Inc.

    Acquisition target mentioned in the earnings release.

  • company
    Sail Biomedicines

    Strategic collaboration partner mentioned in the earnings release.

Read at source← All news

StoryJohnson & Johnson posts Q3 profit plunge but raises full‑year 2026 outlook

Also covered by

6 outlets

Related articles

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

finance.yahoo.com
$JNJMedAI 8/10

Johnson & Johnson’s Javelin Catheter Met Both Trial Goals and Its Impella Data Pushed Back on a Negative Study. Here’s What It Doesn’t Settle

Johnson & Johnson (JNJ) reported positive results for its Javelin catheter, meeting both primary goals in a pivotal study. Impella heart pump data showed lower death rates than a previous negative study. Javelin is still under FDA review, and Impella's recovery depends on future trials. JNJ's cardiovascular unit saw a sales decline, with Impella contributing 1.6% of total revenue. Analysts project a ~25% total return for JNJ stock.

finance.yahoo.com
$JNJMed

TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland

Johnson & Johnson's TREMFYA (guselkumab) has been approved for reimbursement in Ireland for treating moderately to severely active Crohn’s disease and ulcerative colitis. The approval is based on Phase 3 trials showing significant clinical remission rates. According to the company, it offers a novel dual mechanism of action and improved outcomes for patients.

imt.ie
$JNJMed

J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3

Johnson & Johnson (J&J) presented data at a symposium showing lower mortality rates in high-risk PCI patients using Impella heart pumps compared to the CHIP-BCIS3 trial. Three analyses, involving 1,379 patients, reported 30-day mortality rates of 6.1% and 4.7%, and 90-day rates of 6.5%. J&J's heart recovery chief medical officer highlighted the importance of device usage and patient selection. The company continues studying Impella, with PROTECT IV trial results expected in 2027.

medicaldevice-network.com
$JNJHigh

PROTEUS: Perioperative Apalutamide Plus ADT Improves EFS in High-Risk Locally Advanced Prostate Cancer

A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.

endocrinologyadvisor.com